Alcon, a division of Novartis that specializes in eye care, has received approval from the U.S. Food and Drug Administration for AcrySof IQ ReSTOR +3.0D Multifocal Toric Intraocular Lens (IOL), which was developed to treat presbyopia and pre-existing corneal astigmatism. Read More »
Teva Pharmaceuticals Industries' negotiations regarding the violation of the Foreign Corrupt Practices Act have concluded with a resolution of investigations in Ukraine, Mexico and Russia, where the subsidiary pleaded guilty. Read More »
The National Association of Chain Drug Stores, the National Community Pharmacists Association, the American Pharmacists Association and the National Alliance of State Pharmacy Associations have collaborated to send a letter to the incoming Donald Trump administration in that outlines necessary steps that will leverage pharmacy patient care and cut costs resulting from untreated conditions. Read More »
A $1.15 per share dividend was recently declared by Amgen's Board of Directors for the first quarter of next year. Read More »
Pharmacists ranked second behind only nurses in the 2016 Honesty and Ethics survey conducted by Gallup. Read More »
Dr. Giovanni Caforio has been named the Chairman of the Board for Bristol-Myers Squibb's board of directors, effective May 2 at the annual shareholder’s meeting. Read More »
Concert Pharmaceuticals' Phase 2 clinical trial taking place in the United States and involving CTP-656, also known as deuterated ivacaftor, has been initiated. Read More »
Endo International has appointed Patrick Barry as U.S. Branded Pharmaceuticals’ new senior vice president and Matthew Davis as the new senior vice president of research and development at Branded. Read More »
CVS Health President and CEO Larry Merlo recently announced that the CVS Health Charity Classic has surpassed the $20 million milestone in total contributions. Read More »
Tocagen's Phase 2/3 Toca 5 clinical trial has begun enrolling patients in Israel as enrollment in the United States and Canada continues. Read More »
Portola Pharmaceuticals has signed a $50 million loan agreement with Bristol-Myers Squibb and Pfizer that gives Portola supplementary funds to allow for the development and clinical trials of AndexXa. Read More »
Imprimis Pharmaceuticals and Focus Script have collaboratively launched the Correct Compound program, which provides a customizable formulary through the CDF-Logic program as a specialized compound pharmacy care solution. Read More »
Shionogi & Co. Ltd., its subsidiary Shionogi Inc. and Purdue Pharma will launch Symproic, also known as naldemedine, to treat adult patients with chronic non-cancer pain who have opioid-induced constipation. Read More »
Integrated Delivery Networks are continuing to form with the continued growth and mergers of health systems. Read More »
Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of Acanthamoeba Keratitis. Read More »
Ionis Pharmaceuticals posted earnings of $28 million from AstraZeneca due to the finalization of AstraZeneca’s studies supporting IND and the licensing of IONIS-KRAS-2.5Rx, also known as AZD4785. Read More »
Eli Lilly and Co., along with Incyte Corp., have announced that baricitinib received a positive opinion as well as a recommendation for approval from the European Medicines Agency Committee for Medicinal Products for Human Use. Read More »
According to a report published in the most recent issue of the Journal of the American Medical Association, scientists were able to determine that 6 percent of pregnancies after contracting the Zika virus infection resulted in one or more birth defects linked to Zika using data from the U.S. Zika Pregnancy Registry. Read More »
CVS Health recently held its annual Analyst Day, a meeting in which the discussions of strategies for long-term growth will be driven and shareholder value were held. Read More »
Alerts Sign-up
